DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Monteris Smallest Brain Laser Probe Launch; Vesica Health’s AssureMDx Test Launch; Anaut’s Eureka α Japanese Regulatory Approval; Geneoscopy’s Labcorp-Partnered Colon Cancer Test FDA Approval; Novel Omeza® OCM™ Diabetic Foot Ulcers Results; LEO Pharma Phase III Plaque Psoriasis Trial Results
Monteris Launched Smallest Brain Laser Probe on the Market On May 01, 2024, Monteris Medical launched the NeuroBlate® NB3™ FullFire® 1.6mm laser probe, the company’s latest product line innovation for use with their market-leading NeuroBlate System. The NB3 laser probe, which integrates Monteris' patented cooling technology and incorporates cutting-edge advancements in laser fiber technology, stands out as the smallest commercially available laser probe for brain applications. With a single adjustable length, this probe maintains Monteris' edge by enabling multi-trajectory procedures while providing intraoperative convenience for neurosurgeons. Furthermore, the singular NB3…
Nanomedicine Market: Evaluating the Pioneering Innovations and Future Growth Prospects
Nanomedicine has witnessed a remarkable evolution over the past few years, revolutionizing the landscape of medical treatment and diagnosis. Advancements in nanotechnology have paved the way for the development of innovative drug delivery systems, diagnostic tools, and therapeutic agents at the nanoscale level. This evolution has been driven by the need for more targeted and personalized healthcare solutions, minimizing side effects and maximizing efficacy. As per DelveInsight, the global Nanomedicine market is projected to grow at a CAGR of 11.39% from 2024 to 2030. The Nanomedicine market has experienced significant…
Boehringer Ingelheim’s Diabetic Macular Ischemia Study; Novartis’ Mariana Oncology Acquisition; Astellas and Poseida Therapeutics Partnership; Prime Medicine’s PM359 IND; Pfizer’s TIVDAK FDA Approval
Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular ischemia (DMI). The research revealed that BI 764524 was well received when administered intravitreally in both single and multiple doses, successfully achieving its main safety objectives while demonstrating initial indications of effectiveness. Diabetic macular ischemia is a frequent and permanent consequence of diabetic retinopathy with the potential to cause vision loss.…